Repligen Corporation
General ticker "RGEN" information:
- Sector: Health Care
- Industry: Medical - Instruments & Supplies
- Capitalization: $7.9B (TTM average)
Repligen Corporation follows the US Stock Market performance with the rate: 31.1%.
Estimated limits based on current volatility of 3.3%: low 172.67$, high 184.57$
Factors to consider:
- Total employees count: 2000 (+12.5%) as of 2025
- Top business risk factors: Market competition, Supply chain disruptions, Liquidity and credit risks, Acquisition/divestiture risks, Cybersecurity threats
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [129.85$, 196.83$]
- 2026-12-31 to 2027-12-31 estimated range: [132.33$, 200.79$]
Financial Metrics affecting the RGEN estimates:
- Negative: with PPE of 96.9 at the end of fiscal year the price was high
- Negative: Operating cash flow per share per price, % of 1.26 <= 2.37
- Positive: 7.80 < Operating profit margin, % of 8.07
- Positive: 69.38 < Shareholder equity ratio, % of 71.40 <= 81.92
- Positive: 0.90 < Industry operating cash flow per share per price (median), % of 1.58
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: 0.07 < Interest expense per share per price, % of 0.25
Short-term RGEN quotes
Long-term RGEN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $632.36MM | $634.44MM | $738.26MM |
| Operating Expenses | $584.66MM | $669.55MM | $678.68MM |
| Operating Income | $47.70MM | $-35.11MM | $59.58MM |
| Non-Operating Income | $9.00MM | $8.08MM | $2.81MM |
| Interest Expense | $2.50MM | $20.73MM | $23.17MM |
| R&D Expense | $42.72MM | $43.20MM | $54.18MM |
| Income(Loss) | $56.71MM | $-27.04MM | $62.38MM |
| Taxes | $21.11MM | $-1.52MM | $13.49MM |
| Net Income(Loss)* | $35.60MM | $-25.51MM | $48.89MM |
| Stockholders Equity | $1,964.85MM | $1,972.72MM | $2,106.13MM |
| Inventory | $202.32MM | $142.96MM | $170.46MM |
| Assets | $2,831.18MM | $2,829.67MM | $2,949.70MM |
| Operating Cash Flow | $113.92MM | $175.39MM | $117.42MM |
| Capital expenditure | $38.99MM | $32.91MM | $23.52MM |
| Investing Cash Flow | $-123.28MM | $-86.38MM | $-298.47MM |
| Financing Cash Flow | $248.96MM | $-82.90MM | $-15.21MM |
| Earnings Per Share** | $0.64 | $-0.46 | $0.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.